Business Context and Reporting Period
Company: Ocular Therapeutix, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 8, 2017
Reporting Period: Quarter ended June 30, 2017
Context: The Company announced its financial results for the quarter ended June 30, 2017. The full details are contained in a press release furnished as Exhibit 99.1 to this filing.
Key Financial Metrics
The provided filing text serves as a cover document referencing a press release (Exhibit 99.1) for detailed financial data. Consequently, the filing text itself does not provide clear values for the following metrics:
- Revenue
- Profit/Loss
- Cash Flow
- Margins
- Debt
- Liquidity
Material Changes
The filing text does not contain specific data regarding material changes versus the prior comparable period. Investors must refer to the attached press release (Exhibit 99.1) for comparative analysis.
Guidance, Outlook, and Risks
The filing text does not include specific guidance, outlook, management commentary, risks, contingencies, or unusual items. These disclosures are located within the referenced press release (Exhibit 99.1).
Important Facts for Investor Verification
- Verify the specific revenue and net loss figures in the attached press release (Exhibit 99.1), as they are not listed in the 8-K body.
- Confirm the Company's status as an "Emerging Growth Company" and its election not to use the extended transition period for new accounting standards.
- Note that the information in this 8-K is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, limiting liability exposure for the forward-looking statements contained in the referenced press release.
- Review the press release for updates on the Company's principal executive offices located in Bedford, MA.